Tumor neuroglial bem diferenciado (grau II da OMS), difusamente infiltrativo, tipicamente localizado nos hemisférios cerebrais. É composto predominantemente por células que se assemelham morfologicamente à oligodendroglia. As células neoplásicas apresentam núcleos arredondados e homogêneos e, nos cortes de parafina, citoplasma claro e inchado (aparência de “favo de mel”). (Adaptado da OMS)
Introdução
O que você precisa saber de cara
O oligodendroglioma é um tipo de tumor cerebral raro que atinge os hemisférios do cérebro, composto por células que ao microscópio lembram favos de mel. O quadro costuma manifestar seus primeiros sinais durante a idade adulta, embora possa se manifestar em pessoas de todas as idades. No Brasil, o tratamento é estruturado pelo SUS dentro das diretrizes de tumor cerebral no adulto, sendo conduzido conforme a autonomia da equipe de saúde.
Tumor neuroglial bem diferenciado (grau II da OMS), difusamente infiltrativo, tipicamente localizado nos hemisférios cerebrais. É composto predominantemente por células que se assemelham morfologicamente à oligodendroglia. As células neoplásicas apresentam núcleos arredondados e homogêneos e, nos cortes de parafina, citoplasma claro e inchado (aparência de “favo de mel”). (Adaptado da OMS)
Tem tratamento?
Escala de raridade
<1/50kMuito rara
1/20kRara
1/10kPouco freq.
1/5kIncomum
1/2k
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Entender a doença
Do básico ao detalhe, leia no seu ritmo
Preparando trilha educativa...
Sinais e sintomas
O que aparece no corpo e com que frequência cada sintoma acontece
Características mais comuns
Os sintomas variam de pessoa para pessoa. Abaixo estão as 1 características clínicas mais associadas, ordenadas por frequência.
Linha do tempo da pesquisa
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Genética e causas
O que está alterado no DNA e como passa nas famílias
Genes associados
2 genes identificados com associação a esta condição. Padrão de herança: Not applicable.
D-2-hydroxyglutaric aciduria 2
A neurometabolic disorder causing developmental delay, epilepsy, hypotonia, and dysmorphic features. Both a mild and a severe phenotype exist. The severe phenotype is homogeneous and is characterized by early infantile-onset epileptic encephalopathy and cardiomyopathy. The mild phenotype has a more variable clinical presentation. Diagnosis is based on the presence of an excess of D-2-hydroxyglutaric acid in the urine.
Tumor predisposition syndrome 3
An autosomal dominant disorder characterized by an increased risk for the development of various types of benign and malignant neoplasms throughout life, with age-dependent penetrance. Affected individuals can develop neoplasms involving epithelial, mesenchymal, and neuronal tissues, as well as lymphoid and myeloid cancers. The disorder is associated with elongated telomeres.
Medicamentos aprovados (FDA)
1 medicamento encontrado nos registros da FDA americana.
Variantes genéticas (ClinVar)
550 variantes patogênicas registradas no ClinVar.
Classificação de variantes (ClinVar)
Distribuição de 4 variantes classificadas pelo ClinVar.
Vias biológicas (Reactome)
18 vias biológicas associadas aos genes desta condição.
Diagnóstico
Os sinais que médicos procuram e os exames que confirmam
Tratamento e manejo
Remédios, cuidados de apoio e o que precisa acompanhar
Onde tratar no SUS
Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)
🇧🇷 Atendimento SUS — Oligodendroglioma
Selecione um estado ou use sua localização para ver resultados.
Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.
Pesquisa ativa
Ensaios clínicos abertos e novidades científicas recentes
Ensaios em destaque
Com ensaio aberto em 11 países. O ponto verde marca onde há vaga agora.
🟢 Recrutando agora
22 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.
Outros ensaios clínicos
390 ensaios clínicos encontrados, 42 ativos.
Publicações mais relevantes
Mostrando amostra de 200 publicações de um total de 1.616
TET CpG sequence-context-specific DNA demethylation shapes progression of IDH-mutant gliomas.
Treatment decisions in IDH-mutant oligodendrogliomas are shaped by tumor aggressiveness, underscoring the need for objective grading of these malignant brain tumors. We collect 302 primary and recurrent resections from oligodendrogliomas and perform Ki-67 staining, proteomics, and DNA methylation profiling. During tumor progression, DNA methylation of oligodendrogliomas changes along a continuum. This continuum is linked to increased epigenetic aging, methylation of transcription factors and Ki-67+ cell density, and large-scale DNA demethylation. Demethylation correlates with CpG flanking sequences preferred by TET enzymes. We confirm these findings in previously profiled astrocytomas, indicating IDH-mutant gliomas progress along a shared epigenetic axis. We develop an objective DNA methylation-based prognostic continuous grading coefficient (CGCψ) that captures these changes and outperforms the World Health Organization (WHO) grading for oligodendrogliomas. Our findings underscore the potential of DNA methylation-based grading to more accurately reflect tumor biology and inform clinical decision-making in IDH-mutant gliomas.
Association of CDKN2A/B and MTAP deletions in adult-type diffuse gliomas.
In adult-type diffuse gliomas CDKN2A and/or CDKN2B (CDKN2A/B) deletions often co-occur with deletion of MTAP, suggesting that MTAP immunohistochemistry (IHC) may be a surrogate marker of CDKN2A/B status. However, the association between CDKN2A/B and MTAP deletion at the genomic level remains unknown. We assessed CDKN2A/B and MTAP deletions by chromosomal microarray in 333 adult-type diffuse gliomas and performed MTAP IHC on a subset (n = 63). CDKN2A/B and MTAP deletions were detected in 216 and 215 cases, respectively, and were concurrent in 99.5% (215/216). While most tumors with CDKN2A/B homozygous deletion (n = 148) showed concurrent MTAP homozygous deletion (108/148; 73.0%), a subset harbored MTAP heterozygous deletion (39/148; 26.4%). By analyzing the size of the chromosomal alterations, we demonstrate that initial large chromosomal 9p losses result in concurrent heterozygous deletion of CDKN2A/B and MTAP whereas smaller "second hit" deletions leading to homozygous CDKN2A/B deletion do not always encompass the MTAP locus. Discordant CDKN2A/B and MTAP tumors affect the association between MTAP IHC and copy number status of MTAP and CDKN2A/B. These findings suggest that adult-type diffuse gliomas, regardless of IDH status, follow a stereotypic pathway involving concurrent CDKN2A/B and MTAP heterozygous deletion but may diverge for CDKN2A/B and MTAP homozygous deletion.
RNA-based discovery and correction of splicing defects caused by POLR3A missense mutations.
RNA polymerase III-related disorders represent a clinically diverse spectrum of diseases. While pathogenic variants in the POLR3A subunit are most commonly associated with hypomyelinating leukodystrophies, they also contribute to other neurological or systemic deficiencies. Despite this phenotypic variability, many disease-causing POLR3A variants converge mechanistically on altered RNA expression that can impair oligodendrocyte maturation and their myelination capacity. Using CRISPR-dCas13Rx, we investigated whether regions containing disease-causing missense mutations in POLR3A affect RNA splicing in EcR293 and oligodendroglioma cell lines. Our analysis indicates that 20% of the interrogated exon regions of POLR3A harboring disease-causing missense mutations induce significant splicing changes when targeted by an interfering guide RNA (gRNA)/dCas13Rx complex. Minigene assays confirmed that mutations residing in these regions caused splicing aberrations. We then used the CRISPR-dCas13Rx system to identify intron elements that, when targeted with gRNAs, alleviated the splicing defect caused by missense mutations in exon 14 and exon 26. Antisense oligonucleotides (ASOs) derived from these active gRNAs also improved correct splicing in EcR293 and oligodendroglioma cell lines. These findings not only highlight the therapeutic promise of gRNAs and ASOs in rescuing splicing defects caused by POLR3A missense mutations but also establish CRISPR-dCas13Rx as a useful tool for identifying and correcting disease-causing splicing aberrations.
From Data to Decision: Integrating Bioinformatics into Glioma Patient Stratification and Immunotherapy Selection.
Gliomas are notoriously difficult to treat owing to their pronounced heterogeneity and highly variable treatment responses. This reality drives the development of precise diagnostic and prognostic methods. This review explores the modern arsenal of bioinformatic tools aimed at refining diagnosis and stratifying glioma patients by different malignancy grades and types. We perform a comparative analysis of software solutions for processing whole-exome sequencing data, analyzing DNA methylation profiles, and interpreting transcriptomic data, highlighting their key advantages and limited applicability in routine clinical practice. Special emphasis is placed on the contribution of bioinformatics to fundamental oncology, as these tools aid in the discovery of new biomarker genes and potential targets for targeted therapy. The ninth section discusses the role of computational models in predicting immunotherapy efficacy. It demonstrates how integrative data analysis-including tumor mutational burden assessment, characterization of the tumor immune microenvironment, and neoantigen identification-can help identify patients who are most likely to respond to immune checkpoint inhibitors and other immunotherapeutic approaches. The obtained data provide compelling justification for including immunotherapy in standard glioma treatment protocols, provided that candidates are accurately selected based on comprehensive bioinformatic analysis. The tools discussed pave the way for transitioning from an empirical to a personalized approach in glioma patient management. However, we also note that this field remains largely in the preclinical research stage and has not yet revolutionized clinical practice. This review is intended for biological scientists and clinicians who find traditional bioinformatic tools difficult to use.
Decoding the intricacy of insular glioma-lenticulostriate artery relationship: Results from a prospective comparative study of pre and postoperative magnetic resonance angiographic evaluation.
Insular glioma (IG) resection is technically demanding and carries a high risk of postoperative neurological deficits, primarily due to ischemic injury to the middle cerebral artery (MCA) perforators. Understanding pre- and postoperative lenticulostriate artery (LSA) anatomy may clarify the tumor-perforator relationship and its clinical impact. This prospective single-center study analyzed pre- and postoperative three-dimensional time-of-flight magnetic resonance angiography (3D-TOF MRA) to assess IG-LSA relationships. The extent of resection (EOR) and complications were correlated with LSA involvement patterns and postoperative reduction in the number of visible LSAs. LSA involvement patterns included "displaced" (28%), "contact" (56%), and "engulfed" (16%) types. Postoperatively, mean LSA count declined from 3.76 to 3.0 (p = 0.007). Reduction occurred in all patients with engulfed LSAs and in 30% with contact type. Giant IGs were more frequent in contact and engulfed patterns (p = 0.008). Tumors with reduced LSAs were more often oligodendroglioma or glioblastoma than grade 2 astrocytoma (p = 0.004). LSA loss was unrelated to surgical approach but correlated with radical resection (p = 0.019) and neurological deficits (p = 0.001). IGs with LSA engulfment should undergo subtotal resection, whereas contact-type lesions require intraoperative judgment regarding EOR. Radical resection in giant IGs with unsafe tumor-LSA relationships, especially in aggressive histologies, increases the risk of permanent deficits. Not all single-LSA injuries result in lasting impairment. Routine preoperative 3D-TOF MRA is recommended for evaluating IG resectability and minimizing ischemic complications.
Publicações recentes
Immunohistochemical characterization of neural stem cells in brains of adult brachycephalic dogs in comparison with canine oligodendroglioma cells.
SERPINH1, a regulatory factor of oligodendroglioma cell invasion and extracellular matrix secretion, as a novel prognostic biomarker and therapeutic target.
Patterns and quality of therapeutic care for glioma: a population-based study in Belgium between 2016 and 2019.
Seizure-presenting IDH-wildtype glioblastoma and the upregulation of a synaptic signature.
Role of Surrogate Immunohistochemistry Markers in CNS Tumors in the Era of Molecular Diagnostics With Recent Updates.
📚 EuropePMC1.140 artigos no totalmostrando 199
The 1p/19q co-deletion induces targetable and imageable vulnerabilities in glucose metabolism in oligodendrogliomas.
Neuro-oncology[18F]FET-PET in dissecting low-grade oligodendrogliomas.
Journal of neuro-oncologyAnesthesia management in a pregnant woman with a giant temporoparietal anaplastic oligodendroglioma: a case report.
Journal of medical case reportsTET CpG sequence-context-specific DNA demethylation shapes progression of IDH-mutant gliomas.
Cell reports. MedicineIntraoperative Subdural and Postoperative Brainstem Hemorrhage in Glioma Surgery: A Case Report.
The American journal of case reportsRight medial temporal lobe mass in a 25-year-old male.
Brain pathology (Zurich, Switzerland)Molecular analysis of a gliosarcoma with distinct oligodendroglioma and sarcomatous components ("Oligosarcoma").
Brain tumor pathologyExploiting Metabolic Dependencies for Therapeutic Targeting of Brain Cancers.
Cancer lettersPrognostic Impact of Calcification, Corpus Callosum Invasion, and CDKN2A/B Hemizygous Deletion in Oligodendroglioma: A Single-center Retrospective Study.
Neurologia medico-chirurgicaPrognostic relevance of resection at first recurrence in isocitrate dehydrogenase mutant lower-grade glioma: results from a retrospective, single-center, volumetric analysis.
Journal of neuro-oncologyIdentifying clinically relevant cell state interactions in the tumor microenvironment of IDH-mutant gliomas using CSI-TME.
Molecular systems biologyAssociation of CDKN2A/B and MTAP deletions in adult-type diffuse gliomas.
Journal of neuropathology and experimental neurologyBRAF-mutant high-grade glioma with pleomorphic and pseudopapillary features (HPAP): A PLNTY mimic demonstrating tumor progression during longitudinal follow-up.
Neuro-oncology advancesMismatch Between Imaging and Histopathology Diagnosis in High and Low-Grade Gliomas: A Case Report.
JNMA; journal of the Nepal Medical AssociationClinicopathologic, molecular and tumor immune microenvironment features of mismatch repair-deficient glioblastomas in Lynch syndrome: a multicenter study of 29 cases with therapeutic implications.
Acta neuropathologica communicationsCUX1::MET fusion defines an indolent subtype of diffuse low-grade glioma, MAPK pathway-altered.
Acta neuropathologica communicationsA multifocal IDH-mutant glioma with differential response to IDH inhibition: Role of quantitative neuroimaging.
Radiology case reportsProteomics in IDH-mutated diffuse lower-grade glioma: a scoping review.
Neuro-oncology advancesAn Evaluation Study of PET Image Quality Factors in Brain Tumor Diagnosis.
Tomography (Ann Arbor, Mich.)Pediatric Pilocytic Astrocytoma, Rich in Oligodendrocyte-Like Cells: A Diagnostic Challenge.
Journal of pediatric hematology/oncologyFluid Suppression Techniques Combined With Amide Proton Transfer-Weighted Imaging for the Evaluation of Adult-Type Diffuse Gliomas.
Korean journal of radiologyRNA-based discovery and correction of splicing defects caused by POLR3A missense mutations.
Molecular therapy. Nucleic acidsSingle-cell RNA sequencing suggests different progenitor lineages between IDH mutant and IDHwt glioma.
Neuro-oncology advancesGadolinium-Enhanced Portable Ultra-Low Field MRI for Evaluating Various Intracranial Pathologies.
AJNR. American journal of neuroradiologyRCBVmax from DSC Perfusion MRI as a Supportive Imaging Biomarker for Differentiating IDH-Mutant Astrocytomas and Oligodendroglioma.
Clinical neuroradiologyTransfer Learning Strategies for Pathological Foundation Models: A Systematic Evaluation in Brain Tumor Classification.
Pathology international18F-DOPA PET Silence in High-grade Glioma Subtype F: A Distinct Metabolic Phenotype.
Clinical nuclear medicineLong-term administration of the mutant IDH inhibitor DS-1001b suppresses the growth of IDH1-mutant glioma in vitro and in mouse xenograft models and alters epigenetic profiles.
Acta neuropathologicaSynchronous diagnosis of multicentric glioma with distinct isocitrate dehydrogenase molecular profiles: a case report.
CNS oncologyThe Utility of Cystathionine Assessment using proton MR Spectroscopy for the Preoperative Differential Diagnosis of Adult-Type Diffuse Gliomas.
AJNR. American journal of neuroradiologyCytologic and Histologic Features of Oligodendrogliomas in Three Dogs.
Veterinary clinical pathology18F-DOPA-PET and advanced MRI improve treatment response assessment in IDH1/2-mutant gliomas treated with IDH inhibitors.
Clinical cancer research : an official journal of the American Association for Cancer ResearchHematological Malignancies With Multiple Primary Cancers: A Rare Case Presentation.
Case reports in hematology[Expression Characteristics and Prognostic Study of PPP1R13L in Brain Metastases of Lung Adenocarcinoma].
Zhongguo fei ai za zhi = Chinese journal of lung cancerCutting-edge approaches in pet imaging for gliomas: current applications for neurooncologists and the path to theranostic breakthroughs.
European journal of nuclear medicine and molecular imagingReasons driving choice and clinical course of patients with CNS WHO grade 3 IDH mutant glioma receiving vorasidenib after surgery: a pilot experience.
Journal of neuro-oncologyLeveraging transcriptomic, DNA methylation, and molecular alteration data to optimize the classification of IDH-mutant gliomas for therapy selection.
Frontiers in oncologyFrom Data to Decision: Integrating Bioinformatics into Glioma Patient Stratification and Immunotherapy Selection.
International journal of molecular sciencesThe diagnostic value of cortical high-flow sign combined with cystathionine on 1H-MRS for prediction of 1p/19q-codeletion status in IDH-mutant adult-type diffuse glioma.
NeuroradiologyDecoding the intricacy of insular glioma-lenticulostriate artery relationship: Results from a prospective comparative study of pre and postoperative magnetic resonance angiographic evaluation.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of AustralasiaGlioma chemotherapeutic resistance is tied to membrane electrophysiological properties and glycosylation.
Bioengineering & translational medicineThe role of immunohistochemical CIC expression in oligodendrogliomas for recurrence risk stratification.
Clinical neuropathology[Differential diagnosis of high-grade astrocytic gliomas based on CD44, SOX2, and CIRBP gene expression analysis].
Zhurnal voprosy neirokhirurgii imeni N. N. BurdenkoDifferences in Executive Functioning Between Patients with IDH1-Mutant Oligodendroglioma and Astrocytoma Before and After Surgery.
CancersGenomic analysis of PLNTY-like tumor progression into epithelioid glioblastoma: a case report.
Acta neuropathologica communicationsUnsupervised learning of metabolic fingerprints from 3D magnetic resonance spectroscopic imaging enables glioma subtype classification.
Neuro-oncology advances[Polymorphous low-grade neuroepithelial tumor of the young: a molecular pathological study].
Zhonghua bing li xue za zhi = Chinese journal of pathologyIntracerebral hemorrhage risk in glioma patients taking direct oral anticoagulants as compared with low molecular weight heparin.
Neuro-oncology advancesDistinct molecular profiles characterize the spontaneous growth rate of IDHmt low-grade astrocytomas and oligodendrogliomas.
Neuro-oncologyPresenting clinical and radiographic features of diffuse glioma molecular subtypes in accordance with the 2021 CNS5 WHO classification.
Neuro-oncology practiceAnalysis of outcomes of patients with oligodendroglioma with focus on volumetric reduction.
Neuro-oncology practiceFunctional analysis of telomere maintenance mechanisms is more informative than immunohistochemistry for ATRX mutation interpretation in Gliomas.
Acta neuropathologica communicationsBridging Radiology and Pathology: ATRX Loss and T2-FLAIR Mismatch as Early Diagnostic and Prognostic Markers in Diffuse Gliomas.
JPMA. The Journal of the Pakistan Medical AssociationImmunophenotypic characterization of canine oligodendroglioma cells cultured in an oligodendrocyte precursor cell-tailored medium.
The Journal of veterinary medical science[Vorasidenib as monotherapy in grade 2 astrocytoma or oligodendroglioma with an IDH1 R132 or IDH2 R172 mutation].
Bulletin du cancerComparing Isocitrate Dehydrogenase Inhibitors with Procarbazine, Lomustine, and Vincristine Chemotherapy for Oligodendrogliomas.
CancersFree water elimination tractometry reveals local and remote white matter alterations in diffuse gliomas.
Journal of neuro-oncology[Molecular Genetic Analysis of Childhood Brain Tumors].
No shinkei geka. Neurological surgeryPrognostic and predictive determinants in high-grade gliomas: integrating tumor-intrinsic biology with patient and system-level factors.
Frontiers in neurologyHow to predict progression-free survival in patients with grade 2 IDH-mutated diffuse gliomas after surgery: a long-term follow-up analysis.
Frontiers in oncologyClinical predictors of overall survival in elderly oligodendroglioma patients: A Surveillance, Epidemiology, and End Results (SEER) database analysis.
Clinical neurology and neurosurgeryExtraneural Metastasis in Oligodendroglioma: A Comprehensive Review and Outcome Analysis of 90 Cases.
Cancer scienceSuccessful Treatment of Spinal Cord Drop Metastasis From a Forebrain Oligodendroglioma With Radiotherapy.
Veterinary radiology & ultrasound : the official journal of the American College of Veterinary Radiology and the International Veterinary Radiology AssociationA prognostic classification system for extent of resection in IDH-mutant grade 2 glioma: an international, multicentre, retrospective cohort study with external validation by the RANO resect group.
The Lancet. OncologyOptical express-biopsy of gliomas using macroscopic fluorescence lifetime imaging.
Biomedical optics express[Molecular subtype-driven surgical concepts and clinical application in gliomas].
Zhonghua wai ke za zhi [Chinese journal of surgery]Adjuvant chemoradiotherapy with procarbazine, lomustine, and vincristine (PCV) or temozolomide for 1p/19q Co-deleted anaplastic oligodendroglioma: a systematic review and network meta-analysis.
BMC cancerDesigning a web-based platform for dynamic estimation of individualized conditional survival in grade 3 gliomas.
Discover oncologyRisk factors for postoperative malignant progression of lower-grade gliomas: a systematic review and meta-analysis.
Surgical oncologyGlioneuronal and Neuronal Tumors in Adults: WHO 2021 Imaging and Molecular Updates.
AJNR. American journal of neuroradiologyPatient-Reported Outcomes, Neurocognitive Functioning, and Oncologic Results of Pencil-Beam-Scanning Proton Beam Therapy for CNS WHO G2 and G3 IDH1-Mutant Diffuse Adult Glioma: A Single Institution Experience.
International journal of radiation oncology, biology, physicsHealth-related quality of life and cognition in long-term oligodendroglioma survivors: A landmark study.
Neuro-oncologyNew and Emerging Therapies for Patients with Low-Grade Glioma.
CNS drugsEvaluating the super T2-FLAIR mismatch sign in non-contrast-enhancing oligodendroglioma, IDH-mutant, and 1p/19q codeleted.
Japanese journal of clinical oncologyMultimodal treatment with thiotepa, bevacizumab, teniposide, and tunlametinib in a patient with neurofibromatosis type 1-associated oligodendroglioma: a rare case report.
Anti-cancer drugsConcurrence of FGFR1 mutations modulates oncogenesis in glioneuronal tumors.
The EMBO journalSpinal oligodendroglioma: a > 70-year systematic review of current literature.
Journal of neurosurgery. SpineIlluminating glioma surgery: A meta-analysis of Raman spectroscopy for intraoperative decision-making.
Neurosurgical reviewPET imaging pitfall in recurrent oligodendroglioma with drug-resistant epilepsy: illustrative case.
Journal of neurosurgery. Case lessonsCystathionine Detection via Proton Magnetic Resonance Spectroscopy (¹H-MRS) for the Diagnosis of Oligodendroglioma: A Case Report.
CureusCombined temozolomide, immunotherapy and radiotherapy in a patient with anaplastic oligodendroglioma and multiple extracranial metastases: A rare case report.
MedicineExploring the spectrum of central nervous system tumours in carriers of germline POT1 variants.
Journal of medical geneticsStrategy and clinical benefit of first re-resection for recurrent adult-type diffuse glioma: A retrospective cohort analysis.
Med (New York, N.Y.)Investigation of mismatch repair protein expression in glioma.
Annals of diagnostic pathologyOligodendrogliomas, cyclin pathway after the introduction of the molecular 2021 World Health Organization (WHO) criteria.
Brain communicationsStroke Mimic in a Cancer Survivor: A Rare Case of SMART (Stroke-Like Migraine Attacks After Radiation Therapy) Syndrome.
Cureus[Gliomas in adolescents and young adults: Institutional experience].
MedicinaDifferences in advanced radiologic features of glioma subtypes under the 2021 WHO classification of tumors of the central Nervous system.
European journal of radiologyLabel-free fluorescence lifetime imaging for real-time guidance of stereotactic biopsy: A feasibility study in brain cancer patients.
Neuro-oncology advancesLow tumour burden is associated with observation after surgery in patients with grade 2 astrocytoma and oligodendroglioma: results from the prospective multicentre LoG-Glio registry.
Journal of neuro-oncologyPediatric diffuse low-grade glioma with oligodendroglioma-like features: A case report.
Experimental and therapeutic medicineTreatment of glioblastoma with tumor-specific amplitude-modulated radiofrequency electromagnetic fields.
OncotargetCase study: Successful full-course chemotherapy administration in a liver transplant recipient diagnosed with central nervous system World Health Organization Grade 2 IDH mutant/1p-19q co-deleted oligodendroglioma.
Neuro-oncology practicePreoperative peripheral blood routine indicators as predictors of prognosis and diagnosis in glioma under the 2021 World Health Organization classification.
Oncology lettersNavigating the blood-brain barrier to blood-brain tumor barrier transition: microvascular P-glycoprotein and CD146 potentially contribute to glioma grading.
Fluids and barriers of the CNSOpen questions on vorasidenib.
Current opinion in oncologyImpact of Hypertension on the Outcomes of Patients With High-Grade Gliomas: A Propensity-Matched Study From a Global Federated Health Research Network.
CureusRat Glioma 101.8 Tissue Strain: Molecular and Morphological Features.
International journal of molecular sciencesEffective atomic number and electron density from dual-energy CT for differentiating malignant gliomas: Validation using the World Health Organization 2021 brain tumor classification.
The neuroradiology journalUsefulness of amide proton transfer images in the diagnosis of malignant glioma comparison of APT images and 11C-methionine-positron emission tomography.
The neuroradiology journalUptake patterns of Adult-type Non-Enhanced diffuse gliomas on [11C] methionine positron emission tomography : Previous presentations: none.
NeuroradiologyArteriovenous malformation within the velum interpositum.
Polish journal of pathology : official journal of the Polish Society of PathologistsEarly seizure freedom with [18F]fluorodopa positron emission tomography response after isocitrate dehydrogenase inhibition with vorasidenib: First case report.
EpilepsiaHigh-Resolution Mapping of Tumor and Peritumoral Glutamate and Glutamine in Gliomas Using 7-T MRSI.
Radiology. Imaging cancerThe Role of Vimentin, Synaptophysin, and Histone H3 Lysine 27 Methylation (H3K27me) as Surrogate Markers in the Diagnosis and Classification of Oligodendrogliomas and Diffuse Midline Gliomas: A Comprehensive Review.
CureusPrognostic value of [18F]FET-PET in diffuse low-grade (grade 2) gliomas after the 2021 classification of CNS tumors.
European journal of nuclear medicine and molecular imagingFDA Approval Summary: Vorasidenib for IDH-Mutant Grade 2 Astrocytoma or Oligodendroglioma Following Surgery.
Clinical cancer research : an official journal of the American Association for Cancer ResearchA Phase 0 Window of Opportunity Trial of LB100, a Protein Phosphatase 2A Inhibitor, in Patients with Recurrent Gliomas.
medRxiv : the preprint server for health sciencesPerfusion, diffusion, and anatomical MRI characteristics of pathologically confirmed malignant transformation in IDH-mutant gliomas.
Neuro-oncologyrTMS-based neuromodulation for treatment of postoperative aphasia after brain tumor resection: a case report.
NeurocaseExplainable Machine Learning Models for Glioma Subtype Classification and Survival Prediction.
CancersAnalysis of Overall Survival in High-Grade Glioma Patients Treated With Surgery and Adjuvant Therapy.
CureusPrognostic stratification of newly diagnosed IDH-mutant gliomas by [18F]fluoroethyltyrosine and [11C]methionine PET: A retrospective, bicentric cohort study.
Neuro-oncologyDNA methylation analysis reveals an epigenetic signature distinctive of high-grade oligodendroglioma.
Acta neuropathologicaOutcomes and Prognostic Factors in Dogs With Presumed Intracranial Gliomas Treated With Definitive-Intent Intensity Modulated Radiation Therapy: 55 Cases (2014-2023).
Veterinary and comparative oncologyIntra-axial primary brain tumor differentiation: comparing large language models on structured MRI reports vs. radiologists on images.
European radiologyOptic Chiasm and Bilateral Optic Nerve Oligodendroglioma in A 29-Month-Old German Shepherd.
Veterinary ophthalmologyPolymorphous low-grade neuroepithelial tumor of the young.
Surgical neurology internationalEGFR alteration is an adverse prognostic factor in IDH-mutant astrocytoma.
Acta neuropathologicaTumor-initiating genetics and therapy drive divergent molecular evolution in IDH-mutant gliomas.
bioRxiv : the preprint server for biologyA Case of a Fumarate Hydratase Deficient Astrocytoma in Association With a Germline Fumarate Hydratase Mutation With Review of the Literature: Considerations for Patients With Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) Syndrome.
The American journal of surgical pathologyProton therapy for adult type IDH-mutated glioma: Proglio-1, a multicenter retrospective study.
Radiation oncology (London, England)Oligodendrogliomas: findings after classifying the same cohort using pre- and post-World Health Organization (WHO) 2021 criteria.
Brain communicationsSingle center experience of IDH inhibitors in recurrent high-grade gliomas.
Journal of neuro-oncologyFactors associated with cognitive impairment in long-term IDH-mutant glioma survivors.
Journal of neuro-oncologyDistinct molecular profile and outcome of oligodendroglioma, IDH-mutant, 1p/19q-codeleted, and TERTp-wildtype: A grade 1 oligodendroglioma of young patients?
Neuro-oncologyHealth-related quality of life and cognitive functioning in survivors of oligodendroglioma: An international cross-sectional investigation.
Neuro-oncologyDiffuse gliomas: insights into clinical and histopathological features and survival rates from two centers in a middle-income country.
Frontiers in oncologyClinical Outcomes After Proton Therapy Reirradiation for Recurrent Malignant Glioma: Analysis From the Prospective Proton Collaborative Group Registry.
Advances in radiation oncologyWhat do we know about intratumoral functional activity: a scoping review of imaging and intra-surgery results.
NeuroImage. ClinicalIn silico analysis reveals distinct changes in markers of epithelial to mesenchymal transition in glioma subtypes.
Biomolecules & biomedicineRadiotherapeutic approaches in the treatment of adult gliomas.
Advances in cancer researchVorasidenib for IDH-mutant grade 2 gliomas: clinical advances and future directions.
Frontiers in oncologyMTAP and p16 as immunohistochemical surrogates of CDKN2A/B homozygous deletion in central nervous system tumors: A multicentre Italian experience.
Annals of diagnostic pathologyRevisiting prognosis of oligodendroglioma patients in the 2021 WHO classification: incremental value of imaging features.
European radiologyA rare IDH-Mutant glioma case: insights from single-cell transcriptomic analysis of tumor recurrences.
World journal of surgical oncologyDissecting the Dual Drug Candidates Against Glioblastoma and Oligodendroglioma Through Integrated Transcriptome Analysis and Virtual Screening.
Cell biochemistry and biophysicsMolecular Biomarkers of Glioma.
BiomedicinesShared decision-making interventions in neuro-oncology practice: a systematic review.
Journal of neuro-oncologyCorrigendum: High-dose fluorescein reveals unusual confocal endomicroscope imaging of low-grade glioma.
Frontiers in neurologyLow-Grade Glioma in the Differential Diagnosis of Limbic Encephalitis.
CureusDouble fluorescence-guided surgery with 5-ALA and fluorescein sodium in grade 2 and grade 3 adult-type diffuse gliomas: retrospective analysis of 112 cases.
Brain & spineWell-being and coping: Key aspects of unmet need of people living with glioma.
Neuro-oncology practiceChallenges in implementing 2021 WHO CNS tumor classification in a resource-limited setting.
Neuro-oncology practiceA unique case of extra-cerebral diffuse glioneuronal tumor with oligodendroglioma-like features and nuclear clusters.
Radiology case reportsOligodendroglioma: Advances in Molecular Mechanisms and Immunotherapeutic Strategies.
BiomedicinesOligodendroglioma pseudoprogression after radiotherapy in a dog: a case report.
Frontiers in veterinary sciencePSMA radioligand uptake correlates with PSMA expression in high-grade glioma and brain metastasis: insights from a prospective PET-MRI guided multiregional biopsy study.
European journal of nuclear medicine and molecular imagingMedulloblastoma associated with Lynch syndrome: a case report of germline MLH1 variant and tumor molecular characterization.
Investigational new drugsStructural plasticity of the contralesional subfields of hippocampus and amygdala in patients with IDH-mutant astrocytoma and oligodendroglioma.
NeuroradiologyIdentification of intrinsic imaging subtypes using clustering analysis based on dynamic contrast-enhanced magnetic resonance imaging radiomics features for gliomas: preliminary associations with gene expression profiles.
Quantitative imaging in medicine and surgeryEpidemiology of WHO grade 2 and grade 3 gliomas from 2009 to 2021 in Germany.
Journal of neuro-oncologyTumor resection in paramedian structures of the frontal lobe poses a risk for corpus callosum infarction.
Acta neurochirurgicaAlzheimer's disease neuropathological change in younger individuals with IDH-mutant glioma.
Neuro-oncology advancesEvaluating the efficacy of Hip1R, Vimentin, and H3K27me3 as surrogate markers for 1p/19q co-deletion in oligodendrogliomas.
Neuro-oncology advancesLong-Term Remission of Recurrent Anaplastic Oligodendroglioma With WT-1-Specific CD8+ T-Cell Therapy: A Case Report.
Brain tumor research and treatmentGenomic landscape of diffuse glioma revealed by whole genome sequencing.
Nature communicationsRisk Factors and Prognostic Implications of Tumor-Related Epilepsy in Diffuse Glioma Patients: A Real-World Multicenter Study.
Brain and behavior1p and/or 19q polysomy is an adverse prognostic factor in oligodendrogliomas, and easy to detect by automated FISH.
PloS oneTherapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline Rapid Recommendation Update.
Journal of clinical oncology : official journal of the American Society of Clinical OncologyAutomatic smart brain tumor classification and prediction system using deep learning.
Scientific reportsIntegrating Multiplex Immunohistochemistry and Machine Learning for Glioma Subtyping and Prognosis Prediction.
MedCommSupratentorial remote site hemorrhage following elective craniotomy: illustrative case.
Journal of neurosurgery. Case lessonsSuccessful identification and management of a stroke-like migraine attacks after radiation therapy syndrome occurring 36 years after cranial irradiation.
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologiqueHigh-grade glioma: combined use of 5-aminolevulinic acid and intraoperative ultrasound for resection and a predictor algorithm for detection.
Journal of neurosurgeryMolecularly defined oligodendroglioma evolving to osseous metastases.
Journal of neuropathology and experimental neurologyBrain Tumor Characterization Using Multiple MR Parameters From Multi-Contrast EPI With Keyhole (GE-SE EPIK) Including Oxygen Extraction Fraction: A Comparison to O-(2-[18F]Fluoroethyl)-L-Tyrosine (FET) Positron Emission Tomography.
Journal of magnetic resonance imaging : JMRICytology and histology of a high-grade oligodendroglioma with embryonal features in a dog.
Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, IncSpatial synaptic connectivity underlies oligodendroglioma evolution and recurrence.
Research squareNovel strategy to target glioblastoma-initiating cells using a braintropic adeno-associated virus carrying a miR-dependent genome-editing system.
British journal of cancerOncolytic Virotherapy for Relapsed, IDH-Mutant, Grade 3 Astrocytoma: A New Promising Approach - A Case Report.
Case reports in oncologyCurrent trends in the allocation of National Institute of Health funding of brain tumor research.
Neuro-oncology advancesEarly postoperative seizures in patients with adult-type diffuse gliomas: Incidence, risk factors, and clinical outcomes.
Epileptic disorders : international epilepsy journal with videotapeImmunotherapy yields breed-specific worst survival outcomes among three investigated therapies in French bulldogs with high-grade glioma.
Frontiers in veterinary scienceToxicological insights and safety considerations of vorasidenib in grade 2 astrocytoma and oligodendroglioma.
International journal of surgery (London, England)Characteristics, outcome, and prognostic factors of young patients with central nervous system World Health Organization grade 3 oligodendrogliomas IDH-mutant and 1p/19q codeleted: A French POLA network study.
CancerPROshot: Dose Escalation for Non-small Cell Lung Cancer, 5-year Outcomes for Prostate Stereotactic Body Radiation Therapy, Optimal Chemotherapy for Oligodendroglioma, and Omitting Sentinel Lymph Node Biopsy in Early Breast Cancer.
Practical radiation oncologyOligodendroglioma of the Hippocampus: A Case Report and Systematic Review on Therapeutic Approaches of Oligodendroglioma After WHO 2021 Classification.
Pharmaceuticals (Basel, Switzerland)EAAT3 modulation: A potential novel avenue towards remyelination in multiple sclerosis.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapieContemporary Patterns of Care for Low-Grade Glioma in Australia and New Zealand.
Current oncology (Toronto, Ont.)The prevalence of post-therapy epilepsy in patients treated for high-grade glial tumors: a systematic review and meta-analysis.
Medical oncology (Northwood, London, England)α-synuclein expression in glioblastoma restores tumor suppressor function and rescues temozolomide drug resistance.
Cell death & diseaseSurvival prediction with radiomics for patients with IDH mutated lower-grade glioma.
Journal of neuro-oncologyTrends in the Incidence of Cancer Among Adolescents and Young Adults Between 2000 and 2020: A Study Based on French Population-Based Registry Data.
Journal of adolescent and young adult oncologyA dual-genotype IDH-mutant infiltrating glioma, a real oligoastrocytoma in cerebral hemisphere.
IBRO neuroscience reportsLongitudinal analysis of cognitive function in patients treated with postoperative radiotherapy for grade 2 and 3 IDH mutant diffuse glioma.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and OncologyFunctional connectivity between tumor region and resting-state networks as imaging biomarker for overall survival in recurrent gliomas diagnosed by O-(2-[18F]fluoroethyl)-l-tyrosine PET.
Neuro-oncology advancesPreoperative Adult-Type Diffuse Glioma Subtype Prediction with Dynamic Contrast-Enhanced MR Imaging and Diffusion Weighted Imaging in Tumor Cores and Peritumoral Tissue-A Standardized Multicenter Study.
Diagnostics (Basel, Switzerland)Performance Comparison of Diffusion Kurtosis Imaging (DKI), Neurite Orientation Dispersion and Density Imaging (NODDI), and Diffusion Microstructure Imaging (DMI) in Predicting Adult-Type Glioma Subtype-A Pilot Study.
CancersOligosarcoma with chondroid metaplasia in a French bulldog.
The Journal of veterinary medical scienceAPPROACH: Analysis of Proton versus Photon Radiotherapy in Oligodendroglioma and Assessment of Cognitive Health - study protocol paper for a phase III multicentre, open-label randomised controlled trial.
BMJ openProgression of long-term "untreated" oligodendroglioma cases: possible contribution of genomic instability.
Brain tumor pathologyEfficient Detection of Oligodendroglioma With 1p/19q Codeletion Mutation via Methionine PET Imaging: A Promising Diagnostic Approach.
CureusRadiological and histopathological correlations in oligodendroglioma: a comprehensive case report.
The Pan African medical journalctDNA detection in cerebrospinal fluid and plasma and mutational concordance with the primary tumor in a multicenter prospective study of patients with glioma.
Annals of oncology : official journal of the European Society for Medical OncologyDevelopment and validation of a neutrophil extracellular traps-related gene signature for lower-grade gliomas.
Computers in biology and medicineDistinct spatial N-glycan profiles reveal glioblastoma-specific signatures.
The Journal of pathologyRole of the ICF Generic-30 Set in a multidimensional rehabilitation plan for improving functioning in a patient with surgical outcomes of removal of oligodendroglioma: a case report.
BMC musculoskeletal disordersPrognostic impact of tumor size on cancer-specific survival for postoperative WHO grade II oligodendroglioma: a SEER-based study.
Frontiers in surgeryAssociações
Organizações que acompanham esta doença — pra ter apoio e orientação
Ainda não temos associações cadastradas para Oligodendroglioma.
É de uma associação que acompanha esta doença? Fale com a gente →
Doença com base genética
Um médico geneticista pode ajudar no diagnóstico de Oligodendroglioma e no aconselhamento genético da família.
Doenças relacionadas
Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico
Perguntas frequentes
O que as famílias mais perguntam sobre esta doença — cada resposta com a fonte de onde saiu
É um tumor neuroglial bem diferenciado de grau II da OMS, caracterizado por infiltração difusa nos hemisférios cerebrais. Suas células apresentam aspecto microscópico típico com citoplasma claro em forma de favo de mel.
Referências
Fontes citadas no texto, publicações do grafo e bases de dados usadas neste verbete
10 publicações do grafo RarasNet (PubMed) · 6 bases de dados. Títulos, periódicos e PMIDs vêm direto da fonte, sem intermediação de IA.
Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.
Citar este verbete
Raras. (s.d.). Oligodendroglioma. Em Raras — Enciclopédia de Doenças Raras do Brasil. https://raras.org/doenca/oligodendroglioma
Formato APA. Conteúdo sob CC BY 4.0 — reuso livre com atribuição.
Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar
Oligodendroglioma
📋 Origem dos dados
Esta página agrega dados de fontes públicas e oficiais. Dados sobre cobertura no SUS (PCDT, CEAF) são verificados ativamente por agente proativo (ver badge no infobox). Demais dados têm atribuição de fonte + data da última sincronização — clique para abrir o original.
- Doença rara (ontologia)
- fonte: Orphanet
- Identificador unificado
- fonte: MONDO
- Codificação WHO/SUS
- fonte: WHO ICD-10 / DATASUS
- CID-11 (futuro)
- fonte: WHO ICD-11
- NIH/GARD
- fonte: GARD (NIH)
- Indexação biomédica
- fonte: MeSH (NLM)
- Medicamentos aprovados FDA
- fonte: FDA OpenFDA
- Reposicionamento
- fonte: Drug Repurposing Hub
- Ensaios clínicos
- fonte: ClinicalTrials.gov
